Share
5 min read
researchEvidence-based

Is Valiltramiprosate a Magic Pill for APOE4 carriers?

Great results for APOE4s, and a potential short term solution

T
· Reviewed by Dr. Kevin Tran, PharmD

Key takeaways · TL;DR

Valiltramiprosate (ALZ-801), an oral Alzheimer pill taken 265 mg twice daily, showed 52 percent benefit on ADAS-cog and 102 percent benefit on CDR-SB for APOE4 carriers, with zero ARIA events and hippocampal volume protection. The drug blocks toxic amyloid oligomer formation before plaques appear, offering a pill-based alternative to $56,000 annual infusion therapies.

Definition

Amyloid-related imaging abnormalities. ARIA-E means brain swelling and ARIA-H means brain bleeding from antibody therapies.

ARIA is the main safety concern with monoclonal antibody Alzheimer drugs like lecanemab and donanemab, especially in APOE4 homozygotes who have the highest risk.

Definition

A small soluble cluster of amyloid beta protein. Roughly 10 times more neurotoxic than visible plaques.

ALZ-801 vs Antibody Alzheimer Therapies

FeatureALZ-801 (valiltramiprosate)Lecanemab / Donanemab
RouteOral pill 265 mg BIDMonthly IV infusion
ARIA eventsZero in trialSignificant rate, highest in APOE4/4
MRI monitoringNot requiredEvery 3 months
Annual costNot yet pricedAbout $56,000
MechanismPrevents oligomer formationClears formed amyloid

Even though the clinical trial did not meet it's primary end point, the results are very encouraging for APOE4 carriers:

Main results:

  • 52% benefit on ADAS-cog, maintaining above baseline for 52 weeks (p=0.04)

  • 102% benefit on CDR-SB, remaining at baseline for 78 weeks

  • Zero ARIA-E or ARIA-H across all patients

  • Hippocampal volume protection (p=0.04) correlating with clinical benefit (r=0.89)

Brain preservation

  • Preservation of brain volume, a decrease in atrophy

  • Protection across all brain regions

  • Strong correlation between brain preservation and cognitive benefit

  • Some patients showed brain volume increase (neurogenesis?)

And here's the kicker: it's just a pill.

  • 265mg twice a day.

  • No monthly infusions.

  • No MRI monitoring every 3 months.

  • No crazy side effects like ARIA

  • No $56,000 annual cost.

The drug works by preventing oligomers (those invisible toxic proteins that are 10x worse than the plaques we see on scans) from ever forming.

What was also very interesting for me:
Patients with the Arctic mutation have full Alzheimer's with completely CLEAN brain scans.
Their brains are being destroyed by these oligomers we can't even see.
This drug stops that process.

Here's a blog post about Homotaurine a potential short term solution while we wait for Valiltramiprosate https://blog.thephoenix.community/p/alz-801-trial-results

If you are interested to run an experiment with Homotaurine, I have created a post in our Experiment space in the Phoenix Community.

If you are not in, here’s the best time to join us before we move away from the Founding Member period (= lifetime access instead of monthly subscription).
Apply to join the Phoenix Community here.

Cheers,

Kevin

Filed under
researchcognitioncommunity

Discussion

Join the conversation

Your email will never be published. Be respectful and constructive.

FAQ

Frequently asked questions.

What is valiltramiprosate and how does it work?
Valiltramiprosate, also known as ALZ-801, is an oral prodrug of tramiprosate being developed specifically for APOE4 carriers with early Alzheimer disease. It works by preventing amyloid beta oligomers from forming. Oligomers are small soluble clusters of amyloid protein considered 10 times more toxic than the larger plaques seen on brain scans. By blocking oligomer formation upstream, ALZ-801 targets the most damaging species rather than cleaning up plaques after the damage is done. It is taken as a 265 mg pill twice a day.
What were the ALZ-801 clinical trial results for APOE4 carriers?
Although the trial did not meet its primary endpoint, APOE4 carrier subgroup results were encouraging. Patients showed 52 percent benefit on the ADAS-cog cognitive scale, maintaining above baseline for 52 weeks (p equals 0.04), and 102 percent benefit on CDR-SB, holding at baseline for 78 weeks. Hippocampal volume was preserved (p equals 0.04) with a strong correlation of 0.89 between brain preservation and cognitive benefit. Some patients actually showed brain volume increase, raising the possibility of neurogenesis. Zero patients experienced ARIA-E or ARIA-H side effects.
How does ALZ-801 compare to lecanemab and donanemab?
ALZ-801 is an oral pill taken 265 mg twice daily. Lecanemab and donanemab are monthly IV infusions that require MRI monitoring every 3 months to screen for ARIA-E brain swelling and ARIA-H brain bleeds, and they cost around $56,000 per year. ALZ-801 showed zero ARIA events across all patients in its trial, eliminating one of the biggest concerns for APOE4 carriers taking antibody therapies. The pill format also removes infusion center logistics and expensive monitoring, potentially making it far more accessible if approved.
What are amyloid oligomers and why do they matter more than plaques?
Amyloid oligomers are small soluble clusters of amyloid beta protein that form before the visible plaques seen on PET scans. Research suggests oligomers are roughly 10 times more toxic to neurons than fully aggregated plaques. The Arctic mutation case proves this point dramatically: patients with this mutation develop full Alzheimer disease with completely clean brain scans, meaning their brains are being destroyed by oligomers that do not form visible plaques. ALZ-801 targets this invisible toxic species rather than the visible aggregates, a meaningfully different therapeutic mechanism.
What is homotaurine and how does it relate to ALZ-801?
Homotaurine, also known as tramiprosate, is the active compound inside ALZ-801. ALZ-801 is the valine prodrug of tramiprosate, which improves oral bioavailability and reduces gastrointestinal side effects. Because tramiprosate itself was previously marketed as a nutraceutical, some Phoenix Community members are running structured self-experiments with homotaurine as a potential short-term option while waiting for ALZ-801 FDA approval. Phoenix covers the full experimental protocol in its member Experiment space.
Keep reading

Related protocols.